Patients with recurrent low-grade serous ovarian cancer had an 86 percent reduction in tumor size in a new study led by Verastem Oncology, according to a May 25 news release.
Read the full post on Becker's Hospital Review - Healthcare News
Researchers inch closer to treatment for type of ovarian cancer
